Helixgate https://validator.w3.org/feed/docs/rss2.html Home Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis Roche finds another oncology gem in Asia with $1.5B B cell disease partnership Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten rebound DC judge rejects Merck’s IRA case more than three years after it was filed RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug Generate Bio drops as data accidentally leaked ahead of European conference BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer eXoZymes’ Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman Chemical Electrorheoimaging Helps Manage Droplet Viscosity in Real-Time HDX-MS Plus Computational Methods Provide Novel Approach to Study of Protein-Protein Interactions Benchtop Bioreactor Simplifies Macrophage Manufacturing CAR T Production Bottlenecks Best Tackled with AI, Automation, and Skilled Staff STAT+: Eli Lilly’s ‘triple-G’ shows potency, raises concerns STAT+: A biotech turns to Apple Watch to study its Parkinson’s drug Did we undercount Covid deaths by 155,000? STAT+: Pharmalittle: We’re reading about a Lilly weight loss trial, TrumpRx shortcomings, and more STAT+: Data show people racing to chatbots for health advice Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline Wave crashes after obesity trial tracks 1% dip in body weight over 6 months STAT+: The intersection of ‘Apprentice’ and the No Surprises Act STAT+: Democrats prepare for health care overhaul Drug development is booming in China. Should the U.S. view it as a threat or an opportunity? Independent autism committee kicks off efforts to counter RFK Jr., influence Congress  STAT+: Sarepta Therapeutics shares rise on early promise for rare disease drugs Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition STAT+: A 2023 health AI bet that seems to be paying off STAT+: FDA slams Soon-Shiong and ImmunityBio for making ‘false and misleading’ claims about a drug STAT+: How will Trump handle the CDC and ACIP? STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome STAT+: Drug company penalties for paying kickbacks to doctors failed to dent bottom lines, analysis finds All the highlights from STAT’s Breakthrough Summit East Opinion: We’re launching a new CMS pilot program to help children with complex conditions STAT+: FTC strikes proposed deal with CVS over charges its PBM manipulated insulin prices, impeded access STAT+: Novo Nordisk’s high-dose Wegovy approved in the U.S. STAT+: Epic says it has uncovered rot in patient record sharing. Will HHS act?  White House misses deadline to nominate new CDC director STAT+: A surprise opening for health care reforms STAT+: Denali Therapeutics, Corcept Therapeutics win FDA approvals Health influencers talk social media and mental health Eli Lilly’s deal man, Allogene’s off-the-shelf CAR-T, and Merck’s Terns buy STAT+: HHS convenes health care execs, motivational speaker on panel to modernize health care STAT+: FDA approves Rocket gene therapy for rare immune disorder Young startups miss out on biotech venture funding rebound, MassBio says STAT+: ‘We’re on the inside now’: Meet the man building a political empire behind RFK Jr. Cellares, a cell therapy manufacturing specialist, to lay off 100 employees Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test Pennsylvania reports first 2 measles deaths in the U.S. this year, both people unvaccinated STAT+: How Trump’s funding cuts are reshaping the health system